| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/MIB.0B013E318280298F |
| P698 | PubMed publication ID | 23511033 |
| P50 | author | Pyong Woo Park | Q47428657 |
| P2093 | author name string | Jun Xu | |
| Yali Zhang | |||
| Ye Chen | |||
| Fachao Zhi | |||
| Qing Qing | |||
| Shaoheng Zhang | |||
| Qunying Wang | |||
| P2860 | cites work | Inflammatory bowel disease: clinical aspects and established and evolving therapies | Q21957029 |
| Management of Crohn's disease in adults | Q22242349 | ||
| Inflammatory Bowel Disease | Q22248115 | ||
| Acceleration of epithelial cell syndecan-1 shedding by anthrax hemolytic virulence factors | Q25256591 | ||
| Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans | Q28213234 | ||
| Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions | Q28487350 | ||
| Biological roles of oligosaccharides: all of the theories are correct | Q29616459 | ||
| Intestinal mucosal barrier function in health and disease | Q29618086 | ||
| Functions of cell surface heparan sulfate proteoglycans | Q29618521 | ||
| Functional bowel disorders | Q29620328 | ||
| SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis | Q34694466 | ||
| Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice | Q34876266 | ||
| Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies | Q35673130 | ||
| Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function | Q36227233 | ||
| Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge | Q37400576 | ||
| Proteoglycans in health and disease: the multiple roles of syndecan shedding | Q37788814 | ||
| Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. | Q38322333 | ||
| Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. | Q38346025 | ||
| Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy | Q40325540 | ||
| Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy. | Q40480014 | ||
| Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression | Q40562955 | ||
| Mycobacterium tuberculosis mannose-capped lipoarabinomannan can induce NF-kappaB-dependent activation of human immunodeficiency virus type 1 long terminal repeat in T cells | Q41032446 | ||
| Patching a leaky intestine | Q41991004 | ||
| Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response | Q42805166 | ||
| Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression | Q45258065 | ||
| Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study | Q47339211 | ||
| Thomas Kennedy Dalziel 1861-1924. Chronic interstitial enteritis | Q49118481 | ||
| Ability of the heparan sulfate proteoglycan syndecan-1 to participate in bacterial translocation across the intestinal epithelial barrier. | Q51811984 | ||
| Streptococcus pneumoniae sheds syndecan-1 ectodomains through ZmpC, a metalloproteinase virulence factor. | Q53584956 | ||
| Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases. | Q54131635 | ||
| Crohn's disease | Q54165583 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 1025-1033 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Inflammatory Bowel Diseases | Q15749161 |
| P1476 | title | Syndecan-1 and heparanase: potential markers for activity evaluation and differential diagnosis of Crohn's disease. | |
| P478 | volume | 19 |
| Q37137336 | Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease |
| Q37539888 | Cell surface-anchored syndecan-1 ameliorates intestinal inflammation and neutrophil transmigration in ulcerative colitis. |
| Q38721699 | Controversies Revisited: A Systematic Review of the Comorbidity of Depression and Anxiety with Inflammatory Bowel Diseases. |
| Q38831882 | Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. |
| Q40341695 | Heparanase Mediates Intestinal Inflammation and Injury in a Mouse Model of Sepsis |
| Q33761544 | Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice |
| Q90671231 | Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis |
| Q47852995 | Perianal disease is associated with psychiatric co-morbidity in Crohn's disease in remission. |
| Q36752489 | Plasma-Mediated Gut Protection After Hemorrhagic Shock is Lessened in Syndecan-1-/- Mice. |
| Q35942018 | Serum Syndecan-1 Levels and Its Relationship to Disease Activity in Patients with Crohn's Disease |
| Q34499650 | Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer |
| Q86792165 | Soluble Syndecan-1 Levels Are Elevated in Patients with Inflammatory Bowel Disease |
| Q47842891 | Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease. |
| Q89184746 | Soluble syndecans: biomarkers for diseases and therapeutic options |
| Q37192894 | Suppressing Syndecan-1 Shedding Ameliorates Intestinal Epithelial Inflammation through Inhibiting NF-κB Pathway and TNF-α |
| Q36325314 | Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma |
Search more.